

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Andrew P. LEVY

Serial No.: 09/903,463

Filed: July 11, 2001

For: Novel Antioxidant, Nucleic Acid Constructs
Encoding Same, Pharmaceutical Compositions
Containing Same and Use of Same for
Reducing Oxidative-Stress

Examiner: Sheridan Snedden

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Group Art Unit: 1653

Attorney
Docket: 01/22194

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

Each item contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.


Respectfully submitted,


Sol Sheinbein

Registration No. 25,457

Date: November 30, 2003

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/903,463
				Filing Date	07/1/2001
				First Named Inventor	LEVY
				Group Art Unit	1653
				Examiner Name	Sheridan Snedden
Sheet	1	Of	1	Attorney Docket Number	01/2194
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		Melamed-Frank et al, "Structure-Function Analysis of the Antioxidant Properties of Haptoglobin", <i>Blood</i> , 98(13):3693-3698, 2001			
		Langlois et al, "Biological and Clinical Significance of Haptoglobin Polymorphism in Humans", <i>Clinical Chemistry</i> , 42(10):1589-1600, 1996			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.